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It is becoming increasingly clear that single cortical neurons encode
complex and behaviorally relevant signals, but efficient means to
study gene functions in small networks and single neurons in vivo
are still lacking. Here, we establish a method for genetic manipu-
lation and subsequent phenotypic analysis of individual cortical
neurons in vivo. First, lentiviral vectors are used for neuron-specific
gene delivery from -calciumcalmodulin-dependent protein ki-
nase II or Synapsin I promoters, optionally in combination with
gene knockdown by means of U6 promoter-driven expression of
short-interfering RNAs. Second, the phenotypic analysis at the
level of single cortical cells is carried out by using two-photon
microscopy-based techniques: high-resolution two-photon time-
lapse imaging is used to monitor structural dynamics of dendritic
spines and axonal projections, whereas cellular response proper-
ties are analyzed electrophysiologically by two-photon microscopy-
directed whole-cell recordings. This approach is ideally suited for
analysis of gene functions in individual neurons in the intact brain.
patch-clamp recording  two-photon imaging
A ltering expression of specific genes in living organisms hasbecome an invaluable approach to the study of gene func-
tions in systems biology. In mammalian neurobiology, the typical
approach is the generation of transgenic mice or of mice with a
targeted gene disruption (knockout), sometimes in combination
with means to developmentally andor regionally regulate the
onset of the genetic manipulation and the cell type that is
affected (1–3). However, even the most specific genetic designs
affect entire populations of neurons, typically in multiple brain
regions. The current transgenicknockout technologies thus do
not allow targeting of small neuronal networks or individual
neurons in the intact brain. Yet, individual neurons are believed
to critically contribute to network functions in the mammalian
cortex.
The manifold and complex response properties of single
neurons have been a focus of cortical physiology ever since the
groundbreaking work of Hubel and Wiesel (4) in the cat visual
cortex. The emphasis on the analysis of single-neuron activity has
been enforced by studies demonstrating a tight link between
psychophysical judgments and spiking activity of single cortical
neurons in distinct brain regions of primates (5, 6). In addition,
a cause-and-effect evidence for functional significance of indi-
vidual neurons has been provided by a recent study (7) that
showed that intracellular stimulation of single pyramidal neu-
rons in the rat vibrissae motor cortex can drive detectable
movements. Taken together, these experiments demonstrate
that individual cortical neurons encode meaningful and behav-
iorally significant information. The development of methods for
genetic manipulations in individual cortical neurons in vivo is
thus highly desirable.
Recombinant retroviral vectors have been used for stable gene
expression in many cell types (8, 9). One of the most promising
systems for gene delivery to neurons is based on lentiviruses that
infect postmitotic nondividing cells (10, 11). The most commonly
used so-called self-inactivating lentiviral vector contains an
internally placed recombinant promoter that determines the
efficiency of gene expression in different cell types (12).
Here, we present a method that includes a sparse lentiviral
infection of a small number of cortical neurons in vivo, and their
subsequent functional analysis by targeted optical and electro-
physiological methods in anesthetized animals. Because the
temporal and spatial control of the genemanipulations is reliably
achieved by stereotactic delivery of the viral particles, this
method can be used to study gene functions in individual neurons
of defined cortical systems at a postnatal stage of choice.
Methods
All animal experiments were carried out according to the animal
welfare guidelines of the Max Planck Society.
Cloning of Lentiviral Vectors. Flip, ubiquitin promoter, GFP, and
WRE (FUGW) vector (13) cut by PacIBamHI yields a backbone
for the following: Cytomegalovirus (CMV)-IEchicken -actin,
1.7-kb fragment cut SalIEcoRI from pCAGGS-lacZ (14); mouse
Thy1.2, 4-kb fragment cut EcoRIXhoI from puc18-Thy1 (15);
mouse -calciumcalmodulin-dependent protein kinase II (-
CaMKII), 0.4-kb PCR fragment amplified by primers prCK0.45
(CCCTTAATTAACTTGTGGACTAAGTTTGTTCACAT-
CCC) and prCK3 (GCTCTAGAGCTGCCCCCAGAAC-
TAGGGGCCACTCG) from pMM403 template (16); -CaMKII,
1.2-kb PCR fragment amplified by prCK1.25 (CCCTTAAT-
TAACATTATGGCCTTAGGTCACTT) and prCK3 from
pMM403 template; -CaMKII, 2.4-kb fragment cut BamHI from
pMM403; rat Synapsin I 1.1-kb PCR fragment amplified by primers
prSy1.15 (CCCTTAATTAAGGGTTTTGGCTACGTC-
CAGAG) and prSy1.13 (CGCGGATCCAAGGGGCAGT-
GGGTCGGTGGG) from pBL4.3SynCAT template (17); rat Syn-
apsin I 1.1-kb PCR fragment amplified by primers prSy0.55
(CCCTTAATTAACAAGTATCTGGGAAGGGTAAC) and
prSy1.13; and neuron-restrictive silencor elementsimian virus
(SV)40, 0.3-kb fragment cut by KpnIHindIII from pSyNRSE2
SV40luc (18).
Abbreviations: EGFP, enhanced GFP; -CaMKII, -calciumcalmodulin-dependent protein
kinase II; CMV, cytomegalovirus; siRNA, short-interfering RNA; PFA, paraformaldehyde; Pn,
postnatal day n; TPTP, two-photon microscopy targeted-patch; SV40, simian virus 40;
FUGW, Flip, ubiquitin promoter,GFP, and WRE.
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Lentivirus ProductionEnhanced GFP (EGFP) Expression. Lentiviruses
were produced as described (9, 12). Human embryonic kidney
293FT cells (Invitrogen) were transfected by using the calcium-
phosphate method with the expression and two helper, 8.9 and
vesicular stomatitis virus G protein (19, 20), plasmids at 1, 7.5,
and 5.5 g of DNA per 10-cm plate. After 48 h, the supernatants
of four plates were pooled, spun at 780  g for 5 min, filtered at
a 0.45-m pore size, spun at 83,000  g for 1.5 h, and the pellet
was resuspended in 100 l of PBS.
Hippocampal cultures (21) were infected a day after plating
and fixed with 4% paraformaldehyde (PFA) at 14 days in vitro.
For analysis, the cells were imaged with a Leica TCS-NT
confocal microscope, 0.5-m z step, at constant laser intensity
and photomultiplier tube settings. Square regions of interest
(ROIs) were selected over individual cell nuclei (to standardize
the region selection) in maximal projection images; mean fluo-
rescence intensity per area was measured by using IMAGEJ-1.3
software (National Institutes of Health, Bethesda). The in vivo
injections were with similar titer and volume for all viruses,
resulting in an uniform 500- to 600-m diameter infected area.
After an expression period, animals were anesthetized with an
overdose of Halothane and transcardially perfused with 4% PFA
in PBS. Coronal brain sections (100 m) were imaged (0.5- or
1.0-m z step, with stacks up to 60 m). EGFP expression
analysis was done as for the cultured neurons, with the exception
that ROIs were selected from single z sections taken through the
midregion of individual neuronal cell bodies. Care was taken to
analyze cells from the edges of injection sites to avoid bias for
cells with multiple infection at the injection center.
Lentivirus-Based Short-Interfering (siRNA) Expression. The U6 pro-
moter was generated by PCR from mouse genomic DNA with
primers NheI5U6; CCCGCTAGCATCCGACGCCGC-
CATCTCTA and XhoIBbsI 3U6; CCGCTCGAGGAAGAC-
CACAAACAAGGCTTTTCTCCAA (22), and cloned into
pBudCE4.1 (Invitrogen) by means of NheIXhoI, creating a
vector pCMV-U6. The double-stranded hairpin oligo GFPsiRNA
(23) was cloned in pCMV-U6 through BbsIBstBI sites (22). The
U6- GFPsiRNA cassette was recloned into FlkURW through
NheIBstBI (FlkURW was made from FUGW by adding NheI
BstBI linker in the PacI site of FUGW, and replacing EGFP with
dsRed2, Clontech), creating a vector FU6siGURW. For testing
GFPsiRNA-based silencing in neurons, cultures were infected at
1 day in vitro with a high titer of FUGW and at 3 days in vitro with
a low titer of FU6siGURW virus. After 7 days, cells were fixed
in 4% PFA. EGFP fluorescence in the soma region of infected
cells was quantified with IMAGEJ (above).
In Vivo Infection of Cortical Neurons. Wistar rats [aged postnatal
day (P)8–P28] or C57BL6 or NMR1 mice (P10 to P48) were
anesthetized with an i.p. injection of ketamine (100 mgkg)
xylazine (10 mgkg), in some cases, with addition of atropine
(0.02 mgkg). Animals were kept deeply anesthetized as assessed
by monitoring pinch withdrawal, eyelid reflex, corneal reflex,
respiration rate, and vibrissae movements. Body temperature
was maintained at 37°C by using a heating blanket (Watlow).
One to three craniotomies, 300–400 m in diameter, were
drilled above the somatosensory cortex. Viral stock, 30 nl, was
slowly injected, by using an ultraprecise small animal stereotaxic
apparatus (Kopf Instruments, Tujunga, CA) at target depths of
300–500 m below the pia mater with pulled glass pipettes
(Blaubrand intraMARK, tips broken to an outer diameter of
30 m).
In Vivo Two-Photon Imaging. Four to eight days after infections,
animals were anesthetized with urethane (2 gkg of body
weight). A metal plate was attached to the skull with dental
acrylic cement as described (24), and a large craniotomy (1.5–3
mm diameter) was opened. The dura was removed to improve
optical access in rats (this procedure was not necessary in mice).
To dampen heartbeatbreathing-induced brain motion, the cra-
niotomy was filled with agarose (1.5%, type III-A, Sigma) in
normal rat Ringer and covered with a coverslip. In vivo images
were acquired with a custom-built two-photon laser-scanning
microscope with a 40 water-immersion objective lens (0.8
numerical aperture, Zeiss), by using custom-written software (R.
Stepnoski, Lucent Technologies, Murray Hill, NJ, and M. Mu¨l-
ler, Max Planck Institute for Medical Research, Heidelberg). No
apparent changes in morphology resulted from laser illumina-
tion during time-lapse recordings (stacks of 10–34 images, 45- to
300-sec stack interval, 0.5- to 1.5-m z spacing, and 20–350 min
total acquisition time). For overview fluorescence image stack,
a maximum-intensity side projection was created in the z direc-
tion. Consecutive projection images of time-lapse recordings
were aligned based on the position shift of the crosscorrelation
peak by using custom-written macros in NIH IMAGE.
In Vivo Two-Photon Targeted-Patch Recording. Ten to 14 days after
viral delivery, a craniotomy was prepared as for two-photon
imaging (above), but without agar and a glass coverslip. Images
were acquired on a custom-made laser-scanningmicroscope, and
a two-channel whole-area detector (using Hamamatsu R6357
photomultipliers) was used to collect emitted light selected by
interference filters (Chroma Technology, Rockingham, VT;
520BP30 for monitoring EGFP and 610BP40 for Alexa 594
signals). Patch pipettes were fabricated by using nonfilamented
borosilicate glass (OD at 2.0 mm, ID at 1.5 mm, Hilgenberg,
Malsfeld, Germany). The standard intracellular solution was as
follows: 130 mM potassium gluconate, 10 mM sodium gluconate,
10 mMHepes, 10 mM phosphocreatine, 4 mMMgATP, 0.3 mM
GTP, 4 mMNaCl, 0.3–1% biocytin, and Alexa 594 0.05 (pH 7.2).
The liquid junction potential of 7 mV was corrected. The
surface of the cortex was covered with normal rat Ringer.
Recordings were obtained by using an Axoclamp-2B amplifier
(Axon Instruments, Foster City, CA), filtered at 3–10 kHz, and
digitized at 5–20 kHz (ITC-16, Instrutech,Mineola, NY) by using
HEKA software. For whisker stimulation, mechanical stimuli
(6° deflection angle) were delivered by a glass capillary
attached to a piezo apparatus (Physik Instrumente, Karlsruhe,
Germany) for 200 ms at a frequency of 1 Hz (25). After each
successful two-photon microscopy targeted-patch (TPTP) re-
cording, the animals were perfused with 4%PFA in PBS, and the
brains were sectioned tangentially at 100 m, and processed by
cytochrome c oxidase staining (26) and the avidin-biotin-
peroxidase method (27). Cell reconstructions were generated
with NEUROLUCIDA (Microbrightfield, Williston, VT).
Statistics given are for mean  SEM unless otherwise stated.
Table 1. Recombinant promoters used for generation of
lentiviral vectors
Promoter Size, kb Lentiviral vector
CMV-IE-Actin 1.7 FCbAGW
Thy1.2 promoter 4.1 FThGW
-CaMKII 0.4 FCK(0.4)GW
-CaMKII 1.3 FCK(1.3)GW
-CaMKII 2.4 FCK(2.4)GW
Synapsin I 0.5 FSy(0.5)GW
Synapsin I 1.1 FSy(1.1)GW
Syn. I NRSESV40 0.3 FNRSESV40GW
The names of the genes and viral promoter components are indicated in
the left column, the sizes of the recombinant promoter fragments (in kb) in
the middle column, and the abbreviations for the corresponding vectors in the
right column. The names are from the original FUGW promoter. See ref. 13 for
more details.
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Results
To establish efficient pyramidal neuron-specific expression in
the rodent cortex in vivo, we constructed eight lentiviral vectors
that expressed EGFP from different internal promoter se-
quences: a hybrid promoter containing a human CMV enhancer
element in front of a chicken -actin promoter (14), a mouse
Thy1.2 promoter (15), mouse -CaMKII promoters (16) in three
different sizes, rat Synapsin I promoters (17) in two different
sizes, and a hybrid promoter containing two Synapsin I neuron-
restrictive silencer elements in front of an SV40 promoter (18)
(Table 1, and Fig. 6, which is published as supporting informa-
tion on the PNAS web site). The efficiency of expression was
compared with a previously described vector containing the
human ubiquitin C promoter, a construct termed FUGW, which
drives high EGFP expression in various cell types (13).
As a first step to test the efficiency of the promoters, we
compared EGFP expression in hippocampal primary cultures
and organotypic slice cultures infected with the lentiviruses at
normalized titers (Fig. 7, which is published as supporting
information on the PNAS web site). In cultured neurons, the
FUGW vector drove the highest expression, whereas the other
vectors expressed EGFP at slightly lower levels and the FNRSE
SV40GW vector expressed very weakly (Fig. 7c).
Analysis of the Recombinant Promoters in Cortical Neurons in Vivo.To
test the efficiency of the vectors in vivo, we injected viruses into layer
23 somatosensory barrel cortex in P21–P24 animals. After 7 days,
animals were killed, and EGFP fluorescence from individual
neurons was quantified in fixed brain sections (see Methods). The
analysis was restricted to neurons at the periphery of the injection
sites to avoid measurements from superinfected cells in the center
of the injections. As shown in Fig. 1, the-CaMKII promoter-based
vectors FCK(0.4)GWandFCK(1.3)GWdrove the strongest level of
EGFP expression, followed by the Synapsin I promoter-based
vectors FSy(0.5)GW and FSy(1.1)GW. These data are consistent
with developmental up-regulation of endogenous -CaMKII ex-
pression in pyramidal neurons in the second postnatal week (28).
Interestingly, the 2.4-kb-CaMKII promoter, vector FCK(2.4)GW,
drove very weak expression (Fig. 1). Hence, inclusion of the extra
1.1 kb of 5 promoter sequence down-regulates the promoter
activity in vivo in comparison with the shorter constructs. This
finding underscores the importance of testing different-length
promoter fragments in the lentiviral vectors.
Because Synapsin I expression peaks between the second and
third postnatal week (17), the Synapsin I-based vectors may be
suitable for early postnatal expression. To evaluate this possi-
bility, we compared EGFP expression from -CaMKII (1.3 kb)
and Synapsin (1.1 kb) promoters during the second postnatal
week. As expected, the Synapsin I promoter drove approximately
2-fold higher EGFP expression compared with the -CaMKII
promoter in animals injected at P11 and analyzed at P15 or P18
(Fig. 2). Regarding the neuron specificity of expression, at all
developmental stages, the -CaMKII promoter-based expres-
sion was restricted to cortical pyramidal neurons identified by a
typical apical dendrite and dendritic branching in the layer 1
(Fig. 3; see also Movie 1, which is published as supporting
information on the PNAS web site). The Synapsin I promoter
also caused the strongest expression in pyramidal neurons, with
weaker expression in cortical interneurons (Fig. 3 and data not
shown).
To test whether infected cells remain healthy, we examined
the intrinsic biophysical properties of regular spiking layer 23
FCK(1.3)GW-infected neurons by whole-cell patch recordings
in acute slices prepared from P31–P33 rats, 18–20 days after
in vivo injections. All parameters (resting membrane potential,
steady-state input resistance, firing threshold, spike width, and
amplitude) examined in the infected neurons were indistin-
guishable from control, uninfected neurons (Table 2, which is
published as supporting information on the PNAS web site).
We conclude that the 1.1-kb Synapsin I and 1.3-kb -CaMKII
promoter-based vectors drive the highest level of expression in
early postnatal and mature cortical pyramidal neurons in vivo,
respectively.
Fig. 1. Lentivirus-based EGFP expression in cortical neurons in vivo: P21–P28
infection. (a) Examples of lentivirus infected layer 23 neurons in the somato-
sensory cortex. The internal promoter types and corresponding vector names
are indicated at the top and bottom of each image, respectively. The images
are maximum-intensity projections of five z sections separated by 1.0 m,
collected by confocal microscopy from the outer region of the injection sites
(within 100 m from the periphery of an injection area of a 500- to 600-m
diameter) in brain sections. [Scale bar, 10 m (Left Upper) is valid for all
images.] (b) Quantification of EGFP expression based on fluorescent signal
within nuclei of individual infected neurons (n  number of cells analyzed).
The promoter types and corresponding vector names are indicated above and
below the bar graphs, respectively. The values (percent mean  SEM) are
normalized to FUGW expression: FUGW1006.9,n69; FCbAGW62.7
1.8, n  13; FThGW  74.8  3.9, n  19; FCK(0.4)GW  155.1  7.9, n  20;
FCK(1.3)GW  165.7  13.5, n  41; FCK(2.4)GW  41.1  1.0, n  30;
FSy(0.5)GW  142.5  4.7, n  20; FSy(1.1)GW  119.4  5.2, n  20.
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In Vivo Two-Photon Imaging. Two-photon imaging of EGFP-
expressing cells allows visualization of morphological changes,
such as structural dynamics of dendritic spines, in individual
pyramidal neurons in the intact brain (29–31). We tested
whether EGFP expression from the FCK(1.3)GW or
FSy(1.1)GW vectors is sufficient for in vivo two-photon imaging,
at the resolution of dendritic spines and axonal branches. After
7 days of expression, both FCK(1.3)GW- and FSy(1.1)GW-
infected pyramidal neurons could be imaged routinely down to
a depth of 500 m below the pial surface and down to 800 m
under favorable conditions (e.g., removed dura, and lack of large
blood vessels in the field of view) (Fig. 3 and Movie 1).
High-resolution time-lapse imaging of dendritic spines in cortical
layer 1 of P31–P48 mice, after 7–8 days of EGFP expression,
showed negligible amounts of photobleaching (Fig. 4a, and
Movie 2, which is published as supporting information on the
PNASweb site;97.5% of fluorescence intensity remained after
30 min imaging at a 1-min sampling interval). Similarly, EGFP-
labeled axons in layer 1 region adjacent to the injection site could
be imaged for extended time, 1 h when sampled at 45-sec
intervals, or close to 6 h at 5-min intervals (Fig. 4b, and Movie
3, which is published as supporting information on the PNAS
web site;66% of fluorescence intensity remained after 300 min
of imaging of stable structures at a 5-min sampling interval, in
P15–P17 mice after 5–6 days of expression; note the clear
outgrowth of an axonal fiber ending in the time-lapse movie).
TPTP Recording. In the TPTP technique, two-photon imaging is
used to simultaneously visualize EGFP-expressing neurons and
a patch pipette containing a fluorescent dye to visually guide the
pipette toward the labeled neurons and obtain targeted record-
ing in vivo (32). We applied TPTP recording to layer 23
pyramidal neurons in the rat barrel cortex (Fig. 5). Animals were
infected with the FCK(1.3)GW virus between P8 and P11, and
the recordings were obtained between P21 and P24. After
establishing the technique, the frequency of successful targeted
recordings was, on average, one cell per five penetration at-
tempts. Typically, we recorded from one neuron per animal,
which allowed us to compare the sensory-evoked responses to
Fig. 2. Lentivirus-based EGFP expression in cortical neurons in vivo: P11 to
P1518 infection. (a) Examples of infected layer 23 neurons in the somato-
sensory cortex, as in Fig. 1a. The infection period is indicated on the left. (b)
Quantification of EGFP expression normalized to FCK(1.3)GW expression, as in
Fig. 1. The infection period is indicated above the bar graphs. P11–P15:
FCK(1.3)GW 100 13.6, n 10; FSy(1.1)GW 197.9 7.1, n 10; P11-P18:
FCK(1.3)GW  100  10.3, n  8; FSy(1.1)GW  170.4  6.9, n  13.
Fig. 3. In vivo expression pattern of cortical layer 23 infected neurons. Each
image is a maximum-intensity side projection from an overview stack of
fluorescence images recorded by using in vivo two-photon microscopy. Note
the different depth scaling (indicated on the left of each image) and the
different scale bars. (a) FCK(1.3)GW-infected neurons in P28 rat after 7 days of
expression. (b) FSy(1.1)GW-infected neurons in P48 mouse after 8 days of
expression.
Fig. 4. Two-photon time-lapse imaging of dendritic spines and axonal
projections in the mouse cortex. Acquisition times are indicated on the sides
of each image. Each image is a maximum-intensity projection of image stacks
(z step, 1 m) collected in cortical layer 1 in vivo (infected neurons were
located in layer 23). Dashed vertical lines serve as a guide for comparison of
structures over time. (a) Imaging of dendritic spines caused no photobleaching
after 30 min at a 1-min sampling interval, with F (t  30 min) 0.97F (t 
0min). (b) Imaging of axons in a layer 1 region adjacent to the injection site for
5 h at a 5-min sampling interval, with F (t 300 min)0.66F (t 0 min).
Some axonal projection endings, an example indicated by an arrow, showed
directed outgrowth for several micrometers on a time scale of several hours in
young animals (P15–P17 mice). Note the different scale bars in a and b.
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the position of the neuron in the barrel cortex, as revealed by
subsequent reconstruction of the cell’s morphology (27) and
cytochrome c staining of layer four barrels (26) (Fig. 5b).
Recordings lasted, on average, for 30–40 min, and the infected
neurons had normal passive membrane properties, somatic
current injection-evoked firing patterns, and whisker deflection-
evoked sensory responses (Fig. 5 c and d), as compared with
previously reported data obtained by using blind-patch tech-
niques (25, 33).
The main objective of TPTP is to record from genetically
modified cells in vivo. For this aim, the combination of TPTP
recording with RNA interference, a method for gene silencing
through expression of double-stranded siRNAs (34) may be
particularly useful. Recently, the self-inactivating lentiviral vec-
tor was adapted for siRNA-based gene silencing by inserting a
polymerase III promoter (either U6 or H1), which is used to
express siRNA as a fold-back stem–loop structure (23, 35), and
several studies have reported successful gene silencing with
similar retroviral vectors in neurons (36–39). To quantitatively
assess the efficiency of lentiviral vector-based gene silencing in
neurons, we tested siRNA-based knockdown of EGFP expres-
sion in hippocampal primary cultures. To this end, neurons were
infected first with the FUGW virus by using a high titer, leading
to superinfection of all cells, and 3 days later, they were infected
at a low titer with virus coexpressing a hairpin siRNA sequence
against EGFP mRNA, GFPsiRNA (23), and a red fluorescent
protein, dsRed2 (vector FU6siGURW, Fig. 8, which is published
as supporting information on the PNAS web site). Even though
basal EGFP expression in the infected neurons was high, both
due to the efficient transcription driven from the ubiquitin C
promoter in cultured neurons (Fig. 7) and multiple FUGW
integrations per infected cells due to the high titer of the virus,
we observed a strong (70%) decrease of EGFP fluorescence in
GFPsiRNA-expressing neurons (Fig. 8). We conclude that siRNA
driven from the U6 promoter in lentiviral vectors can cause a
significant knockdown of gene expression in neurons, and, in
combination with expression of EGFP, can be used to study gene
functions in single neurons in vivo by two-photon imaging or
TPTP recordings.
Discussion
Lentivirus-Based Gene Expression in Cortical Pyramidal Neurons in
Vivo. The promoters tested here were chosen based on three
criteria: pyramidal neuron-specificity of expression, high tran-
scriptional rate, and a preference for compact promoter size. The
first criterion is important because the viral particles were
pseudotyped with vesicular stomatitis virus (VSV) glycoproteins
that bind nonselectively to membrane phospholipids of all
Fig. 5. Physiological analysis of infected neurons by TPTP recording. (a) An example of an infected in vivo-patched neuron. The EGFP image shows
FCK(1.3)GW-infected layer 23 cells, at a depth of 182 m below pia; The Alexa 594 image shows a patch pipette in a whole-cell configuration on the infected
cell shown in the center on the left. (b) Horizontal projection of dendritic arbors relative to position of layer 4 barrels of the patched infected neuron shown
in a. The cell was reconstructed from tangential sections. (c) Spontaneous activity and firing pattern of FCK(1.3)GW-infected layer 23 neuron shown in a. Top
trace shows typical two-state membrane fluctuations (up and down states) observed in cortical neurons in anesthetized animals; bottom trace shows spiking in
the same cell, elicited with DC current injection. In total, nine regular spiking FCK(1.3)GW-infected neurons were recorded, with average resting membrane
potential, Vrest (mV) 69.3 2.0; steady-state input resistance, Rin (M	) 65.3 9.3; depolarization required for AP initiation (mV) 30.7 1.7.(d) Examples
of whisker deflection-evoked responses in the same cell. Deflection of the D1, D2, and D3 whiskers, as illustrated in the schema on the left, evoked the
corresponding responses shown on the right. The time course of the whisker deflection is shown at the bottom.
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mammalian cells (40). Consequently, the CMV-IE-Actin and
the ubiquitin C promoters drove considerable expression in glia,
as well as neurons. Three promoters, Thy1.2, -CaMKII, and
Synapsin I, were found to be neuron-specific, with the Thy1.2
and -CaMKII promoters labeling selectively pyramidal neu-
rons, as determined from the infected cells’ morphology. This
result confirms that using lentiviruses pseudotyped with the VSV
glycoprotein coat requires the selection of an internal promoter
tailored to the cell type of choice.
In terms of the transcriptional strength, the ubiquitin C
promoter was found to be best suited for expression in cultured
neurons. The Synapsin I (1.1 kb) and -CaMKII (1.3 kb)
promoters drove neuron-specific expression, with the onset of
efficient expression matching transcriptional regulation of en-
dogenous Synapsin I and -CaMKII genes in vivo. The rather low
expression from the Thy1.2 promoter was surprising, because
this promoter drove high expression in transgenic mice (15, 41).
It is possible that we compromised the promoter efficiency to
accommodate for the size limitation of the lentiviral vectors. The
maximum combined size for the promoter and gene of interest
cassette in these vectors is 10 kb (13). Because the original
Thy1.2 transgenic cassette was 6.5 kb (15), we used only the 4-kb
region upstream of the transcriptional start.
Several lentiviral vector types were previously described for
expression of recombinant genes in neurons by using other pro-
moters, e.g., CMV (12, 19, 20), phosphoglycerate kinase 1 (42), or
neuron-specific enolase (43). The Synapsin I (1.1 kb) and
-CaMKII (1.3 kb) promoter-based vectors presented here provide
a highly efficient expression in principal cortical neurons in vivo, and
their compact size indicates that they can be used to express large
genes, perhaps up to8 kb. This size gives the vectors an additional
advantage over other viral systems used for gene delivery to
neurons, where the insert size is often more limited: for example,
the broadly used adenoassociated viruses have promoter and gene
of interest cassette limit of only 4.7 kb (8).
Application of Lentiviral Vectors to Study Gene Functions in Cortical
Neurons in Vivo. Genetic manipulations described here offer
several unique advantages for studying gene functions in cortical
neurons in vivo. First, stereotactic injection makes it easy to
control the delivery of the recombinant genetic material to a
discreet region and to produce expression in a defined time
window. Second, the fact that only a small number of neurons is
affected offers additional benefits. A small population of neu-
rons in the intact brain can be altered in a way that would result
in a lethal phenotype or in an activation of compensatory
mechanisms if the entire brain or whole-brain subregions were
affected. This possibility may allow one to study in vivo functions
of genes that otherwise would be possible to study only by the use
of in vitro methods. Furthermore, f luorescent labeling of sparse
neurons offers a high signal-to-noise resolution (bright labeling
in an otherwise unlabeled tissue) for structural studies by
two-photon imaging.
In summary, we show that the experimental approach de-
scribed here can be used for efficient gene expression or gene
knockdown in a small population of cortical neurons in vivo.
Combination of the lentivirus-based genetic manipulations with
high-resolution two-photon time-lapse imaging or TPTP record-
ing can be applied to study a specific gene product for a function
in single neurons in the intact cortex, with the option to
selectively examine its role(s), either during early postnatal
development or in the adult in a cortical region of choice.
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